1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, October 2018 (p6)

Healthcare Analysis & Statistics in the United States, October 2018 (p6)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

151-180 of about 300 reports

Live-attenuated RSV vaccines

Live-attenuated RSV vaccines

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewIn collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), Sanofi is developing a portfolio of three live-attenuated vaccines (LAVs) for the prevention of serious ...

  • Industries : Chronic Disease
  • Countries : United States, European Union
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

  • $ 599
  • Industry report
  • October 2018

OverviewA US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

  • $ 599
  • Industry report
  • October 2018

OverviewA US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

  • Industries : Mental Health, Pathology
  • Countries : United States
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

  • $ 3000
  • Industry report
  • October 2018

Highlights:New therapies are emerging that harness the immune system to treat cancer, with the PD-1/L1 inhibitor class at the forefrontTrial activity within NSCLC is particularly intense, as Opdivo and ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Datamonitor Healthcare HR+ HER2- KOL Interview – US

Datamonitor Healthcare HR+ HER2- KOL Interview – US

  • $ 1099
  • Industry report
  • September 2018

OverviewDatamonitor Healthcare interviewed a US KOL oncologist on HR+ HER2- breast cancer. The topics discussed include clinical and commercial advantages and disadvantages of marketed and late-stage pipeline ...

  • Industries : Healthcare
  • Countries : United States
Colorectal Cancer Forecast and Market Analysis to 2036, Pharma Intelligence

Colorectal Cancer Forecast and Market Analysis to 2036, Pharma Intelligence

  • $ 22000
  • Industry report
  • September 2018

Disease OverviewColorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiato ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Vertex triple combinations

Vertex triple combinations

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewVertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound with its tezacafto ...

  • Industries : Pathology
  • Countries : United States, European Union
Orkambi

Orkambi

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewOrkambi contains the combination of lumacaftor and ivacaftor, which has the dual mechanism of correcting and potentiating the function of CFTR protein, normalizing chloride conductance in ...

  • Industries : Pathology
  • Countries : United States, European Union
Tobi/Tobi Podhaler

Tobi/Tobi Podhaler

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewTobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients. Long-term treatment with Tobi and Tobi Podhaler treats chronic ...

  • Industries : Pathology
  • Countries : United States, European Union
Cayston

Cayston

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewCayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead. It inhibits cell wall synthesis in aerobic Gram-negative bacteria, including Pseudomonas ...

  • Industries : Therapy
  • Countries : United States, European Union
Symdeko

Symdeko

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewVertex’s Symdeko ([tezacaftor + ivacaftor]) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector compound used as an adjunct to Vertex’s other marketed and developmental ...

  • Industries : Pathology
  • Countries : United States, European Union
Kalydeco

Kalydeco

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewVVertex’s Kalydeco is a CFTR potentiator that acts to increase chloride transport through CFTR. In this way, it mitigates the underlying genetic defect in cystic fibrosis patients with Class ...

  • Industries : Pathology
  • Countries : United States, European Union
Bronchitol

Bronchitol

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewBronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent. Once inhaled, Bronchitol has an osmotic effect that increases ...

  • Industries : Pathology
  • Countries : United States, Germany, United Kingdom
Pulmozyme

Pulmozyme

  • $ 10000
  • Industry report
  • September 2018

Drug OverviewDeveloped by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells. In patients with cystic fibrosis, high ...

  • Industries : Therapy
  • Countries : United States, European Union
Cystic Fibrosis Forecast and Market Analysis to 2025

Cystic Fibrosis Forecast and Market Analysis to 2025

  • $ 22000
  • Industry report
  • September 2018

Disease OverviewCystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, ...

  • Industries : Pathology
  • Countries : European Union, United States
Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

  • $ 4750
  • Industry report
  • August 2018

OVERVIEWThis analysis includes a discussion of Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS) devices, technological innovations, competitors, trends, and expected market growth. Market ...

  • Industries : Mental Health, Pathology
  • Countries : United States, World
Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035, Pharma Intelligence

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035, Pharma Intelligence

  • $ 22000
  • Industry report
  • August 2018

Disease OverviewLung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending ...

  • Industries : Cancer, Pathology
  • Countries : European Union, United States, Japan
Gilotrif

Gilotrif

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewGilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Cemiplimab

Cemiplimab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewCemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Dacomitinib

Dacomitinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewDacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Entrectinib

Entrectinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEntrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Tafinlar

Tafinlar

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type. BRAF is part of the mitogen-activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Iressa

Iressa

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewIressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Tagrisso

Tagrisso

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US

Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US

  • $ 1099
  • Industry report
  • August 2018

OverviewDatamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell ...

  • Industries : Cancer, Pathology
  • Countries : United States
Abraxane

Abraxane

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAbraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an antimicrotubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Tarceva

Tarceva

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Non-Small Cell Lung Cancer KOL Interview – NH, US

Non-Small Cell Lung Cancer KOL Interview – NH, US

  • $ 1099
  • Industry report
  • August 2018

OverviewDatamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell ...

  • Industries : Cancer, Pathology
  • Countries : United States
Seribantumab

Seribantumab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewSeribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3), also known as ErbB3. HER3 is a member of the epidermal growth ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Lorlatinib

Lorlatinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewLorlatinib (Pfizer) is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity. Genetic alterations to ROS1 ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on